Marc Voigt - Immutep CEO
| PRRUF Stock | USD 0.20 0.00 0.00% |
CEO
Mr. Marc Voigt serves as Chief Executive Officer, Executive Director of Prima Biomed Ltd. Marc has more than 18 years of experience in the financial and biotech industry, having joined the Prima team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Primas Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net. IPO AG, a publiclylisted boutique investment bank in Frankfurt where he was focused on IPOs and VC investments. Marc then worked for a number of years as an investment manager for a midsize VC fund based in Berlin, specializing in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectfully, where he handled several successful licensing transactions and financing rounds. since 2016.
| Age | 50 |
| Tenure | 8 years |
| Phone | 61 2 8315 7003 |
| Web | https://www.immutep.com |
Immutep Management Efficiency
The company has return on total asset (ROA) of (0.2296) % which means that it has lost $0.2296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3849) %, meaning that it generated substantial loss on money invested by shareholders. Immutep's management efficiency ratios could be used to measure how well Immutep manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | CEO Age | ||
| Chris Martin | ADC Therapeutics SA | N/A | |
| David Lennon | Aadi Bioscience | 53 | |
| Christopher Martin | ADC Therapeutics SA | 62 | |
| Scott Struthers | Crinetics Pharmaceuticals | 61 | |
| Julie MBA | Zentalis Pharmaceuticals Llc | 60 | |
| Steven MD | Sana Biotechnology | 54 | |
| Raymond Stevens | Structure Therapeutics American | 60 | |
| MBA JD | Viridian Therapeutics | 54 | |
| Robert Blum | Cytokinetics | 60 | |
| Jason Lettmann | Alx Oncology Holdings | 47 | |
| Nadim Ahmed | Cullinan Oncology LLC | 56 | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.23 |
Immutep Limited Leadership Team
Elected by the shareholders, the Immutep's board of directors comprises two types of representatives: Immutep inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immutep. The board's role is to monitor Immutep's management team and ensure that shareholders' interests are well served. Immutep's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immutep's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic MD, Chief Officer | ||
| Deanne LLB, Gen COO | ||
| Indira Naidu, Joint Sec | ||
| Shengfei Fang, F Sec | ||
| Christian Mueller, Director Affairs | ||
| Marc Voigt, CEO, CFO, Chief Bus. Officer, Executive Director, Member of Audit and Risk Committee and Member of Remuneration Committee |
Immutep Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Immutep a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (7.18) % | |||
| Current Valuation | 142.99 M | |||
| Shares Outstanding | 879.09 M | |||
| Shares Owned By Insiders | 4.61 % | |||
| Shares Owned By Institutions | 24.04 % | |||
| Price To Earning | (2.50) X | |||
| Price To Book | 2.81 X | |||
| Price To Sales | 33.12 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Immutep Pink Sheet
Immutep financial ratios help investors to determine whether Immutep Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immutep with respect to the benefits of owning Immutep security.